Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiovascular disease
•
Endocrinology
•
Lipid Disorders
•
Primary Care
Is there any difference in the cardiovascular risk reduction profile of brand name vascepa versus generic icosapent ethyl for patients with hypertriglyceridemia?
Related Questions
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
Do you recommend adding low-dose Aspirin for primary prevention in patients with Type 2 Diabetes on Eliquis for another indication?
Should all kidney transplant patients be started on statin therapy post operatively given their increased risk of CVD?
How often do you recommend performing an advanced lipid panel for monitoring of lipid lowering therapy?
Would you recommend statin initiation in a young adult patient (age < 40) with type 1 diabetes mellitus and LDL cholesterol levels greater than 100 without any cardiovascular risk factors?
How do you counsel patients with metabolic syndrome who decline statin therapy and have low coronary calcium scores regarding their long term CVD risk?
For patients with metabolic syndrome, is it reasonable to wait for the effect of tirzepatide therapy on their lipid profile prior to starting statin therapy?
Would you recommend cinacalcet for patients with recurrent nephrolithiasis who have hypercalciuria despite thiazide diuretic use and who also have an elevated PTH level without localizing parathyroid adenoma on imaging?
Can you use bisphosphonates in a patient with osteoporosis who has had prior avascular necrosis of TMJ due to steroid use?
Would you consider PTH analogue in a patient with mildly elevated PTH?
